Search results
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters via Yahoo Finance· 6 days agoRegeneron has been looking to switch Eylea patients to the high-dose 8 milligram version as the eye...
Regeneron Misses Profit Estimates on Weaker Eylea and Dupixent Sales
US News & World Report· 6 days agoUS News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 5 days agoThis could lead to a delay in the FDA's review, RBC's Abrahams said. "It does not appear this will...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 6 days agoIn August 2023, the FDA approved Eylea HD (higher dose of Eylea) for the treatment of patients with...
Earnings call: Regeneron reports steady growth, prepares for new launches By Investing.com
Investing.com· 5 days ago(NASDAQ: REGN) reported a solid start to 2024, with first-quarter revenues showing a 7% increase...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 6 days ago(Regeneron shares the rights to Dupixent with Sanofi.) Both should continue driving solid top-line...
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation - Regeneron...
Benzinga· 5 days agoEylea US sales fell 16% to $1.2 billion, primarily due to changing market dynamics, resulting in...
Regeneron records mixed results for Q1 as Eylea revenues fall
Crain's New York Business· 5 days agoThe slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...